Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Forget Weight Loss Drugs: Here Is Another Reason to Buy Eli Lilly Stock
03:00am, Thursday, 04'th Jun 2026
Eli Lilly has worked hard to diversify its pipeline. Three new acquisitions will further help decrease its exposure to its core market.
Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry
12:22pm, Wednesday, 03'rd Jun 2026
Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity.
Where Will Eli Lilly Stock be In 2028?
12:09pm, Wednesday, 03'rd Jun 2026
Eli Lilly (NYSE:LLY | LLY Price Prediction) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion.
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
12:05pm, Wednesday, 03'rd Jun 2026
This particular sector may suit cautious and aggressive investors.
Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
09:00am, Wednesday, 03'rd Jun 2026
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs
07:00am, Wednesday, 03'rd Jun 2026
Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli Lilly , worth up to $1.9 billion, to develop new therapies for rare i
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out
03:00am, Wednesday, 03'rd Jun 2026
Eli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate. It could compete with CRISPR Therapeutics, a gene editing-focused biotech.
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
09:30am, Tuesday, 02'nd Jun 2026
Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL
Top 25 High-Growth Dividend Stocks For June 2026
05:14am, Tuesday, 02'nd Jun 2026
The June 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading ~30% below intrinsic value, with a 1.50% average yield and 17.61% five-year dividend growth. I estimate a compel
These 8 Words From Eli Lilly's CEO Have Wall Street Turning Bullish
01:43pm, Monday, 01'st Jun 2026
David Ricks was addressing the pharmaceutical titan's latest hot product.
Eli Lilly Growing at 55% as a Trillion-Dollar Company: ‘These Are NVIDIA-Like Growth Numbers'
11:35am, Monday, 01'st Jun 2026
Macro strategist Jordi Visser delivered a striking observation on a recent episode of The Pomp Podcast with Anthony Pompliano.
Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals
07:04am, Monday, 01'st Jun 2026
U.S. drugmaker Eli Lilly has entered into an agreement to collaborate on and possibly licence experimental medicines from a unit of Haisco Pharmaceutical Group , with potential payments of up to
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with ea
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring
Invesco Summit Fund Q1 2026 Portfolio Update
05:12am, Sunday, 31'st May 2026
At quarter end, Invesco Summit Fund's largest overweights were in industrials, energy and communication services. Within industrials and energy, AI related energy demand has continued to drive spendin
